CDC study shows extended regimens aid patients with MDR-TB

Regimens that involve a wider variety of drugs may help to improve the ultimate outcomes for patients when they have multi-drug resistant tuberculosis (MDR-TB).

Centers for Disease Control and Prevention (CDC) researchers have found that using baseline drug susceptibility testing will help physicians to detect which drugs are most likely to help the patients.

This research, published in PLOS Medicine, involved 1,137 adults who have MDR-TB. They were located in nine nations.

The World Health Organization (WHO) recommends that the treatment regimen for MDR-TB needs a minimum of five drugs that could be effective. Despite this, the scientists found that using six drugs was 36 percent more likely to be successful.

The patients’ responses were measured between the time they received the drugs to their initial sputum culture conversion. They received the drugs each day of the study.

“Our analysis suggests that MDR-TB regimens including more potentially effective drugs than the minimum of five currently recommended by WHO may encourage improved response to treatment in patients with MDR TB,” the study authors said. “In addition, rapid access to high-quality DST results could facilitate the design of more effective individualized regimens."

Organizations in this Story

PLOS Pathogens

Want to get notified whenever we write about PLOS Pathogens ?
Next time we write about PLOS Pathogens, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.